Effects of a New Aminodiphosphonate (Aminohydroxybutylidene Diphosphonate) in Patients With Osteolytic Lesions From Metastases and Myelomatosis

Comparison With Dichloromethylene Diphosphonate

Giuseppe Attardo Parrinello, Giampaolo Merlini, Franco Pavesi, Francesca Crema, Maria L. Fiorentini, Edoardo Ascari

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

We have compared in an open trial the clinical and biochemical effects of a new aminodiphosphonate, aminohydroxybutylidene diphosphonate, with those of dichloromethylene diphosphonate, which has been proved effective. The patients presented extensive and symptomatic bone involvement from multiple myeloma, breast cancer, and other metastatic tumors. The treatment consisted of aminohydroxybutylidene diphosphonate, 2.5 mg/d intravenously for five days, or dichloromethylene diphosphonate, 300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days. Twelve patients treated with aminohydroxybutylidene diphosphonate and 16 patients treated with dichloromethylene diphosphonate were assessable and were followed up for one to six months. Therapy with aminohydroxybutylidene diphosphonate showed a quicker action in reducing bone pain and reduced significantly more the serum calcium level than did therapy with dichloromethylene diphosphonate. Aminohydroxybutylidene diphosphonate therapy also affected urinary calcium levels and hydroxyproline excretion more markedly than did dichloromethylene diphosphonate, although the differences are not statistically significant. However, the biochemical indexes rebounded more quickly in patients treated with aminohydroxybutylidene diphosphonate, indicating that the loading amount (only 12.5 mg) used in this preliminary study is insufficient to sustain a prolonged effect. The effectiveness and lack of side effects render aminohydroxybutylidene diphosphonate an attractive treatment for malignant bone resorption.

Original languageEnglish
Pages (from-to)1629-1633
Number of pages5
JournalArchives of Internal Medicine
Volume147
Issue number9
DOIs
Publication statusPublished - 1987

Fingerprint

Clodronic Acid
Diphosphonates
Multiple Myeloma
Neoplasm Metastasis
Calcium
Therapeutics
Bone and Bones
Hydroxyproline
Bone Resorption
Clinical Trials
Breast Neoplasms
Pain
Serum

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Effects of a New Aminodiphosphonate (Aminohydroxybutylidene Diphosphonate) in Patients With Osteolytic Lesions From Metastases and Myelomatosis : Comparison With Dichloromethylene Diphosphonate. / Attardo Parrinello, Giuseppe; Merlini, Giampaolo; Pavesi, Franco; Crema, Francesca; Fiorentini, Maria L.; Ascari, Edoardo.

In: Archives of Internal Medicine, Vol. 147, No. 9, 1987, p. 1629-1633.

Research output: Contribution to journalArticle

@article{31cd158b9781483caf4e81ac105614c1,
title = "Effects of a New Aminodiphosphonate (Aminohydroxybutylidene Diphosphonate) in Patients With Osteolytic Lesions From Metastases and Myelomatosis: Comparison With Dichloromethylene Diphosphonate",
abstract = "We have compared in an open trial the clinical and biochemical effects of a new aminodiphosphonate, aminohydroxybutylidene diphosphonate, with those of dichloromethylene diphosphonate, which has been proved effective. The patients presented extensive and symptomatic bone involvement from multiple myeloma, breast cancer, and other metastatic tumors. The treatment consisted of aminohydroxybutylidene diphosphonate, 2.5 mg/d intravenously for five days, or dichloromethylene diphosphonate, 300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days. Twelve patients treated with aminohydroxybutylidene diphosphonate and 16 patients treated with dichloromethylene diphosphonate were assessable and were followed up for one to six months. Therapy with aminohydroxybutylidene diphosphonate showed a quicker action in reducing bone pain and reduced significantly more the serum calcium level than did therapy with dichloromethylene diphosphonate. Aminohydroxybutylidene diphosphonate therapy also affected urinary calcium levels and hydroxyproline excretion more markedly than did dichloromethylene diphosphonate, although the differences are not statistically significant. However, the biochemical indexes rebounded more quickly in patients treated with aminohydroxybutylidene diphosphonate, indicating that the loading amount (only 12.5 mg) used in this preliminary study is insufficient to sustain a prolonged effect. The effectiveness and lack of side effects render aminohydroxybutylidene diphosphonate an attractive treatment for malignant bone resorption.",
author = "{Attardo Parrinello}, Giuseppe and Giampaolo Merlini and Franco Pavesi and Francesca Crema and Fiorentini, {Maria L.} and Edoardo Ascari",
year = "1987",
doi = "10.1001/archinte.1987.00370090105018",
language = "English",
volume = "147",
pages = "1629--1633",
journal = "Archives of Internal Medicine",
issn = "0003-9926",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Effects of a New Aminodiphosphonate (Aminohydroxybutylidene Diphosphonate) in Patients With Osteolytic Lesions From Metastases and Myelomatosis

T2 - Comparison With Dichloromethylene Diphosphonate

AU - Attardo Parrinello, Giuseppe

AU - Merlini, Giampaolo

AU - Pavesi, Franco

AU - Crema, Francesca

AU - Fiorentini, Maria L.

AU - Ascari, Edoardo

PY - 1987

Y1 - 1987

N2 - We have compared in an open trial the clinical and biochemical effects of a new aminodiphosphonate, aminohydroxybutylidene diphosphonate, with those of dichloromethylene diphosphonate, which has been proved effective. The patients presented extensive and symptomatic bone involvement from multiple myeloma, breast cancer, and other metastatic tumors. The treatment consisted of aminohydroxybutylidene diphosphonate, 2.5 mg/d intravenously for five days, or dichloromethylene diphosphonate, 300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days. Twelve patients treated with aminohydroxybutylidene diphosphonate and 16 patients treated with dichloromethylene diphosphonate were assessable and were followed up for one to six months. Therapy with aminohydroxybutylidene diphosphonate showed a quicker action in reducing bone pain and reduced significantly more the serum calcium level than did therapy with dichloromethylene diphosphonate. Aminohydroxybutylidene diphosphonate therapy also affected urinary calcium levels and hydroxyproline excretion more markedly than did dichloromethylene diphosphonate, although the differences are not statistically significant. However, the biochemical indexes rebounded more quickly in patients treated with aminohydroxybutylidene diphosphonate, indicating that the loading amount (only 12.5 mg) used in this preliminary study is insufficient to sustain a prolonged effect. The effectiveness and lack of side effects render aminohydroxybutylidene diphosphonate an attractive treatment for malignant bone resorption.

AB - We have compared in an open trial the clinical and biochemical effects of a new aminodiphosphonate, aminohydroxybutylidene diphosphonate, with those of dichloromethylene diphosphonate, which has been proved effective. The patients presented extensive and symptomatic bone involvement from multiple myeloma, breast cancer, and other metastatic tumors. The treatment consisted of aminohydroxybutylidene diphosphonate, 2.5 mg/d intravenously for five days, or dichloromethylene diphosphonate, 300 mg/d intravenously for seven days, followed by 100 mg/d intramuscularly for ten days. Twelve patients treated with aminohydroxybutylidene diphosphonate and 16 patients treated with dichloromethylene diphosphonate were assessable and were followed up for one to six months. Therapy with aminohydroxybutylidene diphosphonate showed a quicker action in reducing bone pain and reduced significantly more the serum calcium level than did therapy with dichloromethylene diphosphonate. Aminohydroxybutylidene diphosphonate therapy also affected urinary calcium levels and hydroxyproline excretion more markedly than did dichloromethylene diphosphonate, although the differences are not statistically significant. However, the biochemical indexes rebounded more quickly in patients treated with aminohydroxybutylidene diphosphonate, indicating that the loading amount (only 12.5 mg) used in this preliminary study is insufficient to sustain a prolonged effect. The effectiveness and lack of side effects render aminohydroxybutylidene diphosphonate an attractive treatment for malignant bone resorption.

UR - http://www.scopus.com/inward/record.url?scp=0023230963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023230963&partnerID=8YFLogxK

U2 - 10.1001/archinte.1987.00370090105018

DO - 10.1001/archinte.1987.00370090105018

M3 - Article

VL - 147

SP - 1629

EP - 1633

JO - Archives of Internal Medicine

JF - Archives of Internal Medicine

SN - 0003-9926

IS - 9

ER -